alexa Immunological Effect of Anti-Epidermal Growth Factor Re

Journal of Immunooncology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Immunological Effect of Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies in Squamous Cell Carcinoma of the Head and Neck (HNSCC): the Present and the Future

Denaro Nerina1*, Elvio Grazioso Russi2, Lo Nigro Cristiana3 and Marco Carlo Merlano1

1Oncology Department Santa Croce e Carle, General Hospital, Via Michele Coppino 21 12100 Cuneo, Italy

2Radiotherapy Department Santa Croce e Carle, General Hospital, Via Michele Coppino 21 12100 Cuneo, Italy

3Oncology Translational Laboratory, Oncology Department, Santa Croce e Carle, General Hospital Via Michele Coppino, 21 12100 Cuneo, Italy

Corresponding Author:
Denaro Nerina
Oncology Department Santa Croce e Carle
General Hospital, Via Michele Coppino 21 12100 Cuneo, Italy
Tel: +39 0171616350
Fax: +39 0171616360
E-mail: [email protected]

Rec date: Jan 29, 2016; Acc date: Mar 10, 2016; Pub date: Mar 14, 2016

Citation: Nerina D, Russi EG, Cristiana LN, Merlano MC (2016) Immunological Effect of Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies in Squamous Cell Carcinoma of the Head and Neck (HNSCC): the Present and the Future. J Immunooncol 2:103. doi:10.4172/joi.1000103

Copyright: © 2016 Nerina D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 
To read the full article Peer-reviewed Article PDF image

Abstract

Targeted therapy with anti Epidermal growth factor receptor (EGFR) monoclonal Antibodies (mAbs) offers the potential to improve outcomes in HNSCC. EGFR is over-expressed in 80 to 90% of HNSCC and leads to tumor cell proliferation and invasion. HNSCC is an immunogenic disease, it has a multiplicity of non-mutually exclusive mechanisms of immune suppression (e.g., reduction CD8+ cell influx and altered function of intra-tumoral CD4+ cells). Monoclonal Abs possess the potential advantage of recruiting immune effector mechanisms, such as complement-dependent cytotoxicity (CDC) and Ab-dependent cellular cytotoxicity (ADCC), as additional mechanisms of tumor cell killing. However immunotherapy with the EGFR-specific mAb Cetuximab is clinically effective in 10-20% of patients. There is a need to further understand the immunological mechanism of the mAbs to optimize the design of a target-based immunotherapy.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords